10-Q: Hypha Labs Reports Significant Losses Amid Business Pivot to Mushroom Accelerator, Raises Going Concern Doubts

Sentiment:

Quarterly Report 13 June 2025 4:39 PM

Hypha Labs, Inc. reported a substantial net loss of $1.98 million for the six months ended March 31, 2025, as it transitions from cannabis testing to developing a mushroom accelerator, raising significant concerns about its ability to continue as a going concern.

Capital raiseThe company intends to raise funds to complete the development and testing of its accelerator over the next 6 to 12 months.Funds are also needed to finance the initial launch of commercial sales of its accelerator device.The company plans to raise such funds through either the sale of equity or debt securities.A potential Regulation A offering is being considered following the 6 to 12-month development period.

Worse than expectedThe net loss from continuing operations significantly increased to $1,981,463 for the six months ended March 31, 2025, compared to a loss of $197,689 in the prior year period.Total operating expenses surged by 147%, primarily due to a 489% increase in general and administrative expenses, which included a substantial non-cash compensation expense.The company's cash balance is critically low at $21,093, and it has a negative working capital of $1,546,801, indicating severe liquidity issues.The accumulated deficit has grown to $22,528,889, reflecting ongoing and increasing losses.

Summary

Hypha Labs, Inc. has fully transitioned from its former cannabis testing business (Digipath Labs) to focus on the research, development, and commercialization of the Hypha Micropearl accelerator, a home appliance for producing nutritionally beneficial mushrooms.
For the six months ended March 31, 2025, the company reported no revenues from continuing operations, compared to $1,635,299 from discontinued operations in the prior year period.
The net loss from continuing operations significantly widened to $1,981,463 for the six months ended March 31, 2025, from a loss of $197,689 in the same period last year.
Total operating expenses surged by 147% to $1,974,426, primarily driven by a 489% increase in general and administrative expenses to $1,090,578, which includes a non-cash compensation expense of $968,356 related to the issuance of Series C Preferred shares to the sole officer.
Professional fees also increased by 111% to $883,848, including $456,063 in non-cash, stock-based compensation.
As of March 31, 2025, the company had a cash balance of only $21,093, negative working capital of $1,546,801, and an accumulated deficit of $22,528,889.
The company's disclosure controls and procedures were deemed not effective as of March 31, 2025.
Several convertible notes payable, totaling $1,078,235, had their maturity dates extended to July 31, 2025, with some notes previously in default.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to severe financial distress, including a significant net loss, critically low cash, negative working capital, and an accumulated deficit, which collectively raise substantial doubt about the company's ability to continue as a going concern. While there's a strategic pivot, the financial state is dire.

Positives

The company has fully divested its cannabis testing business, allowing for a focused pivot to the new mushroom accelerator technology.
Hypha Products Inc. was formed to specifically engage in the research, development, and commercialization of the Hypha Micropearl accelerator, indicating a clear strategic direction.
The company recovered $50,000 in previously written-off receivables during the six months ended March 31, 2025.
Interest income of $8,000 was recognized for the six months ended March 31, 2025.

Negatives

The company reported a significant net loss of $1,981,463 for the six months ended March 31, 2025, a substantial increase from the $197,689 loss in the prior year period.
Cash on hand is critically low at $21,093 as of March 31, 2025, down from $91,166 in September 2024.
The company has a negative working capital of $1,546,801 and an accumulated deficit of $22,528,889, raising substantial doubt about its ability to continue as a going concern.
Operating expenses increased significantly by 147%, primarily due to a 489% increase in general and administrative expenses, including a large non-cash compensation expense of $968,356 for Series C Preferred shares issued to the sole officer.
Professional fees increased by 111%, partly due to non-cash stock-based compensation.
The company has no revenues from its continuing operations for the periods presented.
Several convertible notes payable were in default prior to their recent maturity extensions.

Risks

**Going Concern Risk**: The company's negative working capital, accumulated recurring losses, and low cash balance raise substantial doubt about its ability to continue operations.
**Financing Risk**: The company needs to raise significant funds to complete development, testing, and commercial launch of its new product, with no assurance of success, and potential for substantial dilution to existing stockholders.
**Development and Commercialization Risk**: There is no assurance that the company will achieve its goal of marketing the Hypha Micropearl accelerator by the end of calendar year 2025, or at all.
**Internal Control Deficiencies**: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, indicating potential weaknesses in financial reporting and compliance.
**Debt Default Risk**: Some convertible notes were previously in default, and while maturity dates have been extended, the company's financial position suggests ongoing challenges in meeting debt obligations.

Future Outlook

Hypha Labs intends to continue the design, development, and testing of the Hypha Micropearl accelerator over the next six months. The company aims to produce a limited number of accelerators at its headquarters for testing with mycologists and functional mushroom experts. Upon successful testing, it plans to seek a manufacturing arrangement outside the United States for commercial sale, with a goal to market the accelerator by the end of calendar year 2025. The company is also evaluating future investments into potential acquisition targets.

Management Comments

"We intend to continue the design, development and testing of the Hypha Micropearl accelerator over the next six months."
"Our goal is to be in the position to market the Hypha Micropearl accelerator by the end of calendar year 2025, although there can be no assurance we will achieve our goal in this time period, or at all."
"The Company will seek to raise funds to complete the development and testing of its accelerator over the next 6 to 12 months and to fund the initial launch of commercial sales of its accelerator device."
"There can be no assurance that we will be successful in achieving these objectives, becoming profitable or continuing our business without either a temporary interruption or a permanent cessation."
"Additional financing may result in substantial dilution to existing stockholders."

Industry Context

Hypha Labs is undergoing a significant strategic pivot, exiting the cannabis and hemp testing market, which has faced regulatory and market challenges, to enter the nascent and growing functional mushroom and home appliance market. This shift positions the company in a new industry with different competitive dynamics and consumer trends, moving from a service-based model to a product-centric one. The functional mushroom market is experiencing increased consumer interest in health and wellness, potentially offering new growth avenues, but also requiring substantial R&D and market penetration efforts.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
New Preferred Stock Series Creation	The board of directors approved the creation of a new series of preferred stock, designated as Series D Preferred, and reserved 60,000,000 shares of common stock for its conversion. The Certificate of Designation was filed and became effective on April 2, 2025.	2025-04-02	This creates a new class of preferred stock that ranks junior to Series A and B Preferred but senior to Series C Preferred and common stock in liquidation. It has no voting rights generally but requires a majority vote for material adverse changes to its terms. This could impact future capital raises and shareholder structure.
Internal Control Effectiveness	Management concluded that the company's disclosure controls and procedures were not effective at the reasonable assurance level as of March 31, 2025.	2025-03-31	This indicates a material weakness in internal controls over financial reporting, which could lead to errors in financial statements or non-compliance with SEC reporting requirements, increasing operational and regulatory risk.

Legal Proceedings

No material pending legal proceedings to which the company is a party or to which any of its property is subject, nor any such proceedings known to be contemplated by governmental authorities.

Related Party Transactions

During the six months ended March 31, 2025, the company incurred $60,000 in compensation expense for services provided by its sole officer, with $30,000 owed as of March 31, 2025.
The company accrued $10,000 in fees for services provided by its directors during the six months ended March 31, 2025, with a total of $17,500 accrued as of March 31, 2025.
As of March 31, 2025, $7,401 in reimbursable expenses were owed to the officer and directors.
On December 10, 2024, the sole officer, A. Stone Douglass, purchased 1,000 shares of Series C Preferred stock for $100 cash. The company recorded $968,356 as compensation expense, representing the excess value of these shares.

Stakeholder Impact

**Shareholders**: Face significant dilution risk from potential future equity raises, and substantial value erosion due to ongoing losses and the going concern doubt. The issuance of Series C Preferred stock to the CEO at a nominal price, resulting in a large non-cash compensation expense, could be viewed negatively.
**Employees**: May face uncertainty regarding job security and company stability due to the going concern issue and the early stage of the new business venture.
**Creditors**: Face increased risk of default given the company's low cash, negative working capital, and accumulated deficit, despite recent debt maturity extensions.
**Customers (Future)**: The success of the new mushroom accelerator business is uncertain, impacting potential future customers' ability to rely on the company's products.

Next Steps

Continue design, development, and testing of the Hypha Micropearl accelerator over the next six months.
Produce a limited number of accelerators at headquarters for testing with mycologists and functional mushroom experts.
Seek to enter into a manufacturing arrangement outside the United States for commercial sale upon successful design and testing.
Goal to market the Hypha Micropearl accelerator by the end of calendar year 2025.
Seek to raise funds through equity or debt securities, potentially via a Regulation A offering, within the next 6 to 12 months.
Evaluate future investments into potential acquisition targets.

Key Dates

Date	Description
2010-10-05	Hypha Labs, Inc. incorporated in Nevada.
2012-03-05	2012 Stock Incentive Plan originally adopted.
2016-06-21	2012 Stock Incentive Plan amended and restated.
2018-11-08	Company received proceeds of $350,000 on a senior secured convertible note.
2018-12-28	Start date of period during which Northwest Analytical Labs, Inc. was loaned a total of $95,000.
2019-06-13	End date of period during which Northwest Analytical Labs, Inc. was loaned a total of $95,000.
2019-09-23	Company received proceeds of $200,000 on a senior secured convertible note.
2020-02-11	Company completed the sale of a 9% Secured Convertible Promissory Note in the principal amount of $50,000.
2020-03-11	VSSL Enterprises, Ltd. acquired.
2020-09-30	Maturity date of senior secured convertible note (from Sep 23, 2019) extended to August 10, 2022, and conversion price amended to $0.03 per share.
2020-09-30	Maturity date of senior secured convertible note (from Nov 8, 2018) extended to August 10, 2022, and conversion price amended to $0.03 per share.
2020-12-28	Conversion price of 9% Secured Convertible Promissory Note amended to $0.03 per share, and promissory note increased to $60,000.
2020-12-29	Note holder converted $10,000 of principal into 333,334 shares of common stock.
2021-02-22	Noteholder converted $90,000 of principal into 3,000,000 shares of common stock.
2021-09-30	Senior secured convertible note amended to add outstanding short term notes and accrued interest, making the outstanding balance $355,469.
2022-03-05	2012 Stock Incentive Plan terminated.
2022-07-20	Series C Preferred stock designated.
2022-08-08	Note holder agreed to extend the maturity date of the 9% Secured Convertible Promissory Note to February 11, 2024.
2022-10-01	Company further extended the maturity date of the senior secured convertible note (from Sep 23, 2019) to February 11, 2024.
2022-10-01	Company further extended the maturity date of the senior secured convertible note (from Nov 8, 2018) to February 11, 2024.
2022-10-01	Company entered into a senior secured convertible note for $362,765.
2022-12-08	Company entered into an Asset Purchase Agreement with Invictus Wealth Group.
2023-04-20	Company and Digipath Labs entered into an Asset Purchase Agreement with DPL NV, LLC.
2023-04-30	Company, Digipath Labs and Buyer entered into a Management Services Agreement.
2023-06-30	Original due date for first principal payment of $100,000 from Invictus.
2023-09-30	Original due date for second principal payment of $100,000 from Invictus.
2023-10-17	Nevada Cannabis Compliance Board (CCB) approval obtained for Management Services Agreement.
2023-12-31	Original maturity date for the Invictus Note and final payment of $425,000 due.
2024-01-18	Company received approval from the CCB to transfer assets pursuant to the Purchase Agreement.
2024-01-22	Company amended senior secured convertible note (from Sep 23, 2019) to extend maturity to February 11, 2025 and reduced conversion price to $0.01.
2024-01-22	Note holder agreed to extend maturity date of senior secured convertible note (from Oct 1, 2022) to February 11, 2025.
2024-01-29	Holder converted $40,000 of senior secured convertible note (from Nov 8, 2018) into common shares.
2024-02-20	Company completed the sale of the net assets of Digipath Labs, Inc. and changed its name to Hypha Labs, Inc.
2024-03-31	Amended maturity date for the Invictus Note (first amendment).
2024-04-18	Hypha Products Inc. formed.
2024-05-06	Company entered into a lease for its operating and office facility.
2024-06-24	Company and Buyer settled the final amount owed on the working capital adjustment for an additional payment of $42,835.
2024-06-30	Due date for principal payment of $50,000 from Invictus (second amended agreement).
2024-09-30	Due date for principal payment of $50,000 from Invictus (second amended agreement).
2024-10-15	Company entered into a secured credit facility with a third party.
2024-11-27	Company entered into an amendment to the Asset Purchase Agreement with Buyer for early release of escrow deposit.
2024-12-03	Company received the escrow deposit amount.
2024-12-10	Company entered into a Securities Purchase Agreement with A. Stone Douglass for Series C Preferred stock.
2024-12-31	Due date for principal payment of $50,000 from Invictus (second amended agreement).
2024-12-31	9% Secured Convertible Promissory Note was in default.
2025-01-21	Company issued 500,000 shares of common stock to an outside consultant.
2025-02-10	Facility holder agreed to extend the maturity date of the secured credit facility to July 31, 2025.
2025-02-10	Note holder agreed to further extend the maturity date of the senior secured convertible note (from Sep 23, 2019) to July 31, 2025.
2025-02-10	Note holder agreed to further extend the maturity date of the senior secured convertible note (from Nov 8, 2018) to July 31, 2025.
2025-02-10	Note holder agreed to further extend the maturity date of the senior secured convertible note (from Oct 1, 2022) to July 31, 2025.
2025-02-14	Note holder agreed to further extend the maturity date of the 9% Secured Convertible Promissory Note to July 31, 2025.
2025-02-17	Company issued 9,500,000 shares of common stock to outside consultants.
2025-02-20	Company issued 75,000 shares of common stock.
2025-03-31	End of the current reporting period for this Form 10-Q.
2025-03-31	Due date for principal payment of $100,000 from Invictus (second amended agreement).
2025-04-01	Board of directors approved the creation of Series D Preferred stock.
2025-04-02	Certificate of Designation of the Series D Preferred Stock filed and declared effective.
2025-06-13	Date of filing of this Quarterly Report on Form 10-Q.
2025-06-30	Due date for principal payment of $100,000 from Invictus (second amended agreement).
2025-07-31	Extended maturity date for several convertible notes and the secured credit facility.
2025-09-30	Due date for principal payment of $125,000 from Invictus (second amended agreement).
2025-12-31	Final payment of $216,780 due from Invictus (second amended agreement).
2025-12-31	Goal to market the Hypha Micropearl accelerator by the end of this calendar year.
2026-05-31	Operating and office facility lease agreement expires.

Recommendation

strong sell

Keywords

Hypha Labs, Mushroom Accelerator, Functional Mushrooms, SEC Filing, 10-Q, Financial Results, Going Concern, Business Pivot, Biotechnology, Consumer Appliances, Preferred Stock, Convertible Notes, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.